Positive modulators of the AMPA receptor

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 10, 2000, Pages 1539-1548

  Grove, S J A ^a   Rogers, G A ^a   Zhang, M Q ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; AMPA; Chemical structures; CNS applications; Positive modulators; Schizophrenia

Indexed keywords

1 ANISOYL 2 PYRROLIDINONE; 4 AMINOBUTYRIC ACID; 4 [2 (PHENYLSULPHONYLAMINO) ETHYLTHIO] 2,6 DIFLUORO PHENOXYACETAMIDE; 4H 1,2,4 PYRIDOTHIAZINE 1,1 DIOXIDE DERIVATIVE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA METHYLBENZYLAMINE; ALPRAZOLAM; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; AMPAKINE; ANIRACETAM; BENZAMIDE; BENZAMIDE DERIVATIVE; BENZOFURAZAN DERIVATIVE; BENZOTHIADIAZINE; BENZOTHIAPYRAZOLE; BENZOXAZINE DERIVATIVE; BENZOYL PIPERIDINE; CYCLOHEXENE; CYCLOTHIAZIDE; DIAZOXIDE; DIZOCILPINE; GLUTAMIC ACID; PYRROLIDINE DERIVATIVE; QUINAZOLINE; QUINAZOLINE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; HUMAN CELL; MEDICAL LITERATURE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PATENT; PATHOGENESIS; RAT; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

EID: 0033815899     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.10.1539     Document Type: Review

References (39)

1. 3H]AMPA binding sites in rat brain as determined by quantitative autoradiography
2. Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation
3. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learned-dependant task
4. Facilitation of glutamate receptors enhances memory
5. A centrally active drug that modulates AMPA receptor gated currents
6. Centally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo
7. Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat
8. Facilitation of ofactory learning by a modulator of AMPA receptors
9. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats
10. Effects of a memory enhancing drug on DL-(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus
11. Psychological effects of a drug that facilitates brain AMPA receptors
12. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans
13. Enhancement by an ampakine of memory encoding in humans
14. Facilitative effects of the ampakine CX516 on short-term memory in rats: Correlations with hippocampal neuronal activity
15. Benzodiazepines block long-term potentiation in slices of hippocampus and piriform cortex
16. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients
17. Prefrontal function in schizophrenia: Confounds and controversies
18. Cortical maldevelopment, anti-psychotic drugs and schizophrenia: A search for common ground
19. Immunoautoradiographic evidence for a loss of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia
20. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers
21. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
22. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study
23. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
24. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
25. Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice
26. Sub anaesthetic doses of ketamine stimulate psychosis in schizophrenia
27. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses
28. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam
29. Aniracetam has proportionately small effects on synapses expressing long-term potentiation: Evidence that receptor changes subserve LTP
30. Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus
31. Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography
32. Diazoxide blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurones
33. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease
34. Modulating excitatory synaptic neurotransmission: Potential treatment for neurological disease?
35. Structurally novel AMPA potentiators: New opportunities for drug development
36. Enantioselective synthesis of a pyrrolobenzothiadiazine derivative S 18986, a new AMPA receptor positive modulator
37. 4H-1,2,4-pyrido thiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2,4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-
38. A novel allosteric potentiator of AMPA receptors: 4-[2-(phenyl-sulfonylamino) ethylthio]-2,6-difluoro-phenoxy acetamide